nct_id: NCT05785754
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-03-27'
study_start_date: '2023-06-28'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Doxorubicin'
  - drug_name: 'Drug: Tebentafusp'
  - drug_name: 'Drug: DCSZ11'
  - drug_name: 'Drug: Pembrolizumab'
long_title: A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study
  to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as
  a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
last_updated: '2025-06-26'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: DynamiCure Biotechnology
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 320
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Selected Inclusion Criteria:'
- "1. Male or female patients \u2265 18 years of age."
- 2. Be willing and able to provide written informed consent for the study.
- 3. Patients in Phase 1a must have a histologically or cytologically documented,
  advanced (metastatic and/or unresectable) solid tumor that has progressed on or
  after standard therapy (relapsed/refractory patients; patients must have failed
  at least one prior line of therapy) or for whom there is no effective standard therapy
  based on the Investigator's judgment.
- 'Note: Patients with glioblastoma (GBM) or other central nervous system(CNS) tumors
  may participate if they are on stable or decreasing corticosteroid levels not exceeding
  2 mg/day dexamethasone (or equivalent doses of other corticosteroids) within 7 days
  of the first dose of study drug or do not require corticosteroids.'
- 'Note: For patients who are intolerant to or refuse standard-of-care therapy for
  recurrent disease, reasons must be documented.'
- '4. Patients in Phase 1b Dose Optimization/Expansion must have one of the following:'
- 1. Non-squamous NSCLC for which prior standard first-line treatment containing an
  anti-PD-(1/L1) checkpoint inhibitor alone or in combination has failed and that
  has progressed to no more than 2 prior systemic therapies. Patients must not have
  presented with disease progression during the first 3 months of treatment with first
  line anti-PD-(1/L1)-containing therapy. Patients must have had documented disease
  progression per RECIST 1.1 within 12 weeks from the last dose of anti-PD-1/L1 mAb
  to be considered to have failed an anti-PD-(1/L1) mAb containing therapy. The initial
  evidence of disease progression to anti-PD-1/L1 mAb containing therapy needs to
  be confirmed by a second assessment no less than 4 weeks from the date of the first
  documented disease progression.
- 'Note: Patients with known driver mutations/genomic aberrations (i.e., EGFR, B-Raf
  proto-oncogene mutation V600E \[BRAF V600E\], and ROS proto-oncogene 1 \[ROS1\]
  sensitizing mutations, neurotrophic receptor tyrosine kinase \[NRTK\] gene fusions,
  and ALK rearrangements) are not eligible.'
- 'Note: Patients with rapid clinical progression are excluded from participation.'
- "2. Immunotherapy-na\xEFve microsatellite stable-CRC (MSS-CRC) that failed or was\
  \ intolerant to \u2265 2 lines of therapy and that progressed on/after no more than\
  \ 4 lines of therapy."
- 'Note: Patients must have received prior treatment with fluoropyrimidine-, oxaliplatin-,
  and irinotecan-containing regimens if indicated. Patients eligible for treatment
  with an approved and available targeted therapy must have been offered such therapy
  prior to enrollment. Adjuvant chemotherapy will be considered a prior line of therapy
  if the patient progressed while on or within 6 months of completing adjuvant treatment.'
- '5. Patients in Phase 1b Standard-of-Care Combination Lead-in/Expansions must have
  one of the following:'
- "1. Histologically confirmed, anthracycline na\xEFve, metastatic or locally advanced,\
  \ unresectable soft-tissue sarcoma for which doxorubicin monotherapy is indicated.\
  \ Note: Ewing sarcoma, gastrointestinal stromal tumor (GIST), and Kaposi sarcoma\
  \ are excluded."
- 2. Histologically confirmed, metastatic or advanced, unresectable uveal melanoma
  that are eligible for treatment with tebentafusp monotherapy. Patients should not
  have received more than 4 doses of tebentafusp at the target dose level of 68 mcg.
- 6. Patients must have a lesion not previously irradiated that can be biopsied with
  acceptable clinical risk and agree to have a fresh biopsy at Screening and on treatment;
  except patients with GBM or other CNS tumors. Every effort must be made to take
  the second biopsy from the same lesion of the biopsy at Screening.
- 7. Patients must have at least 1 measurable lesion according to RECIST 1.1; except
  for patients enrolled in monotherapy dose levels 1 and 2.
- 1. A lesion in a previously irradiated area is eligible to be considered as a measurable
  disease as long as there is objective evidence of progression of the lesion before
  study enrollment.
- 2. Patients must have at least 1 measurable lesion for inclusion that will not undergo
  biopsy.
- 3. Patients with GBM must meet the RANO criteria of measurable disease for the post-gadolinium
  primary T1WI.
- '8. Patients with previously treated CNS metastases may participate provided that:'
- "1. They are stable (i.e., without evidence of progression by magnetic resonance\
  \ imaging \\[MRI\\]) for \u2265 4 weeks prior to the first dose of study drug),\
  \ and"
- 2. All neurologic symptoms have returned to baseline, and
- 3. For patients enrolled in expansion cohorts, have not required steroid treatment
  for at least 14 days before the first dose of study intervention Patients with signs
  or symptoms suggestive of CNS metastases, must have brain imaging performed to confirm
  the absence of detectable CNS disease within 2 weeks prior to the first dose of
  study drug.
- 'Note: This criterion does not apply to patients with GBM or other CNS tumors.'
- 9. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. Patients
  enrolled in expansion cohorts must have an ECOG performance status of 0 or 1.
- '10. Adequate organ function and bone marrow reserve as indicated by the following
  laboratory assessments performed within 10 days prior to the first dose of study
  drug:'
- "1. Bone marrow function: absolute neutrophil count (ANC) \u2265 1000/\xB5L, ANC\
  \ \u2265 1500/\xB5L in expansions; hemoglobin \u2265 9 g/dL (criteria must be met\
  \ without erythropoietin dependency and without packed red blood cell (pRBC) transfusion\
  \ within last 2 weeks) ; platelet count \u2265 75,000/\xB5L, platelet count \u2265\
  \ 100,000/\xB5L in expansions."
- "2. Hepatic function: Total serum bilirubin \u2264 1.5 \xD7 the upper limit of normal\
  \ (ULN) or direct bilirubin \u2264 ULN for patients with total bilirubin levels\
  \ \\> 1.5 x ULN; serum aspartate aminotransferase (AST)/alanine aminotransferase\
  \ (ALT), \u2264 2.5 \xD7 ULN (\u2264 5 \xD7 ULN in the presence of hepatic metastases)."
- 'Note: Patients with inherited disorders of bilirubin metabolism should be discussed
  with the Sponsor.'
- "3. Renal function: Creatinine clearance \u2265 30 mL/minute based on Cockcroft-Gault\
  \ estimation."
- "4. Coagulation profile: Prothrombin time (PT)-international normalized ratio (INR)/activated\
  \ partial thromboplastin time (aPTT) \u2264 1.5 \xD7 ULN. Patients on a stable,\
  \ maintenance regimen of anticoagulant therapy for at least 30 days prior to the\
  \ first dose of study drug may have PT/INR measurements \\> 1.5 \xD7 ULN if, in\
  \ the opinion of the Investigator, the patient is suitable for the study. An adequate\
  \ rationale must be provided to the Sponsor prior to enrollment."
- 11. Have recovered to Grade 1 or baseline from all toxicity associated with previous
  therapy or have the toxicity established as sequela.
- "Note: Neuropathy and/or hearing impairment \u2264Grade 2, any grade alopecia, or\
  \ autoimmune endocrinopathies with stable replacement therapy are permitted."
- 12. Patients receiving a combination with standard-of-care must meet established
  treatment criteria for the respective standard-of-care agent(s).
- '13. Patients with human immunodeficiency virus (HIV) must have well controlled
  disease on antiretroviral therapy (ART), defined as:'
- "1. Patients on ART must have a CD4+ T-cell count \u2265350 cells/mm3 at the time\
  \ of screening."
- 2. Patients on ART must have achieved and maintained virologic suppression defined
  as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) using
  the locally available assay at the time of screening and for at least 12 weeks before
  screening.
- 3. Patients on ART must have been on a stable regimen, without changes in drugs
  or dose modification, for at least 4 weeks before study entry (Day 1) and agree
  to continue ART throughout the study.
- 4. Patients must not have had any AIDS-defining opportunistic infections within
  the past 12 months or any history of Kaposi's sarcoma and/or Multicentric Castleman's
  Disease.
- '14. Female patients must agree to not breastfeed through 5 months after the last
  dose of study drug and must meet 1 of the following:'
- 1. Postmenopausal for at least 1 year before the screening visit, or
- 2. Surgically sterile, or
- 3. Agree to practice 1 highly effective method and 1 additional effective (barrier)
  method of contraception at the same time, from the time of signing of the ICF through
  5 months after the last dose of study, or
- 4. Agree to practice true abstinence during the entire study treatment period and
  through 5 months after the last dose of study drug, when this is in line with the
  preferred and usual lifestyle of the patient. Periodic abstinence \[e.g., calendar,
  ovulation, symptothermal, postovulation methods\], withdrawal, spermicides only,
  and lactational amenorrhea are not acceptable methods of contraception. Female and
  male condoms should not be used together.
- '15. Male patients, even if surgically sterilized (i.e., status postvasectomy) must
  agree to 1 of the following:'
- 1. Agree to practice effective barrier contraception from the time of signing of
  the ICF through 2 months after the last dose of DCSZ11, or
- 2. Agree to practice true abstinence from the time of signing of the ICF through
  2 months after the last dose of study drug, when this is in line with the preferred
  and usual lifestyle of the patient. Periodic abstinence \[e.g., calendar, ovulation,
  symptothermal, postovulation methods\], withdrawal, spermicides only, and lactational
  amenorrhea are not acceptable methods of contraception. Female and male condoms
  should not be used together.
- 16. Must be willing and able to comply with clinic visits and procedures outlined
  in the study protocol.
- 'Criteria for Exclusion:'
- 1. Received systemic anticancer treatments or investigational products within 28
  days before the first dose of study drug or 5 half-lives, whichever is shorter.
- "Note: Low-dose steroids (oral prednisone \u226410 mg per day or equivalent), hormonal\
  \ therapy for prostate cancer or breast cancer (as adjuvant treatment), and treatment\
  \ with bisphosphonates and receptor activator of nuclear factor kappa-\u0392 ligand\
  \ (RANKL) inhibitors are allowed."
- "2. Received extended field radiotherapy \u22644 weeks before the start of treatment\
  \ (\u22647 days for limited field radiation for palliation outside the chest or\
  \ brain) or has radiation related toxicities requiring corticosteroid treatment."
- 3. Patients with second malignancy within the previous 3 years, except treated basal
  cell or localized squamous skin carcinomas, localized prostate cancer, cervical
  carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ,
  or other malignancy for which the patient is not on active anticancer therapy. These
  patients must be discussed with the Sponsor prior to enrollment.
- 4. Patients with known active CNS metastases and or carcinomatous meningitis.
- 5. Systemic arterial thrombotic or embolic events, such as cerebrovascular accident
  (including ischemic attacks) or hemoptysis within 3 months prior to the first dose
  of study drug
- 6. Systemic venous thrombotic events (e.g., deep vein thrombosis) or pulmonary arterial
  events (e.g., pulmonary embolism) within 1 month prior to the first dose of study
  drug. Patients with venous thrombotic events prior to the first dose of study drug
  on stable anticoagulation therapy are eligible.
- 7. Left ventricular ejection fraction (LVEF) \< 50%.
- 8. Major surgery within 4 weeks and minor surgery within 2 weeks of the first dose
  of study drug; following surgeries, all surgical wounds must be healed and free
  of infection or dehiscence. Patients must have recovered and not have ongoing surgical
  complications.
- "9. Marked proteinuria \u2265 2 g/24 hours and/or nephrotic syndrome. Patients with\
  \ proteinuria 2+ or greater urine dipstick reading should undergo further assessment,\
  \ e.g., a 24-hour urine collection."
- 10. Known allergy or hypersensitivity to any component of the study drugs or, for
  patients receiving the imaging agent, any component of the imaging agent.
- '11. For patients receiving a combination with pembrolizumab:'
- 1. Received any prior immunotherapy and was discontinued from that treatment due
  to a Grade 3 or higher immune-related adverse event (except endocrine disorders
  that can be treated with replacement therapy) or was discontinued from that treatment
  due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis.
- "2. Severe hypersensitivity (\u2265Grade 3) to pembrolizumab and/or any of its excipients."
- 3. Autoimmune disease requiring systemic immunosuppressive therapy within the past
  2 years. Hormone therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
  replacement therapy for adrenal or pituitary insufficiency) is not considered an
  excluded form of systemic treatment of an autoimmune disease.
- 4. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
  (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
  immunosuppressive therapy within 7 days prior the first dose of study intervention.
- 5. History of radiation therapy to the lung that is \>30 Gy within 6 months of the
  first dose of study treatment
- 6. History of (noninfectious) pneumonitis/interstitial lung disease that required
  steroids or has current pneumonitis/interstitial lung disease.
- 7. History of allogeneic tissue or solid organ transplant.
- 12. Receipt of any live or live-attenuated vaccine within 4 weeks of initiation
  of study treatment. Administration of killed vaccines is allowed.
- 13. Has active infection requiring systemic therapy.
- '14. Patients that are hepatitis B virus surface antigen (HBsAg) seropositive and
  with detectable hepatitis B virus (HBV) viral load. Note: Patients with positive
  HBsAg can been enrolled if they have received HBV antiviral therapy for at least
  4 weeks, and have undetectable HBV viral load prior to initiation of study treatment.
  Patients should remain on antiviral therapy throughout study intervention and follow
  local guidelines for HBV antiviral therapy post completion of study intervention.'
- '15. Patients with history of hepatitis C virus (HCV) infection and detectable HCV
  viral load at screening. Note: Patients must have completed curative antiviral therapy
  at least 4 weeks prior to initiation of study treatment.'
- "16. History of any of the following \u22646 months before first dose: congestive\
  \ heart failure New York Heart Association Grade III or IV, unstable angina, myocardial\
  \ infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension\
  \ despite appropriate medical therapy, ongoing symptomatic cardiac arrhythmias \\\
  >Grade 2, or any other serious cardiac condition (e.g., pericardial effusion or\
  \ restrictive cardiomyopathy). Chronic atrial fibrillation on stable anticoagulant\
  \ therapy is allowed."
- 17. History or current evidence of any condition, therapy, laboratory abnormality,
  psychiatric illness, social circumstances, or other circumstance that might compromise
  the ability to provide informed consent, confound the results of the study, or interfere
  with the patient's ability to cooperate with the requirements of the study, such
  that it is not in the best interest of the patient to participate, in the opinion
  of the treating investigator.
- 18. Female patients who are pregnant or lactating and breastfeeding.
short_title: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced
  or Metastatic Solid Tumors
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: DynamiCure Biotechnology
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a multicenter, open-label, Phase 1 study to assess the effects of
  DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic
  solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization
  Phase (Phase 1b).
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Phase 1a Dose Escalation Monotherapy
      arm_internal_id: 0
      arm_description: Dose escalation to investigate the safety and tolerability
        of DCSZ11.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: DCSZ11'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Phase 1a Dose Escalation Combination
      arm_internal_id: 1
      arm_description: Dose escalation to investigate safety and tolerability, and
        determine DCSZ11 Phase 1b doses in combination with pembrolizumab.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: DCSZ11'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
    - arm_code: Phase 1b Dose Expansions
      arm_internal_id: 2
      arm_description: Dose expansion to further investigate the safety, tolerability,
        and preliminary evidence of antitumor activity of the combination with pembrolizumab
        in select tumor indications.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: DCSZ11'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
    - arm_code: Phase 1b Standard of Care
      arm_internal_id: 3
      arm_description: 'Phase 1b - Standard-of-Care (SOC) Combinations Safety Lead-in/
        Expansion in Select Indications A safety lead-in using the BOIN design followed
        by a Simon two-stage like design will be used to evaluate DCSZ11 in combination
        with standard of care in select indications. Patients will receive DCSZ11
        IV at one of the dose escalation dose levels/schedule (or dose/schedule selected
        for optimization/expansion). Once the safety lead-in is completed, a Bayesian
        continuous toxicity monitoring will be used to monitor for unacceptable toxicity
        in expansions.


        The following SOC combination expansion cohorts will be enrolled:


        * 1b SOC Cohort 1: Doxorubicin combination in soft tissue sarcoma

        * 1b SOC Cohort 2: Tebentafusp combination in uveal melanoma'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Doxorubicin'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Tebentafusp'
        level_internal_id: 1
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Advanced
          - Unresectable
          - Recurrent
          - Refractory
          - Metastatic
          - Locally Advanced
          oncotree_primary_diagnosis: _SOLID_
      - and:
        - genomic:
            hugo_symbol: EGFR
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: BRAF
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: ROS1
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: NTRK
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: ALK
            variant_category: '!Mutation'
